A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(10 sites)

United States

Michigan Alzheimer's Disease Center, Ann Arbor, Michigan

University of Pennsylvania, Philadelphia, Pennsylvania

Vanderbilt University Medical Center, Nashville, Tennessee

University of Texas at Houston, Houston, Texas

Australia

Eastern Health-Box Hill Hospital, Melbourne, Victoria